首页|lncRNA CASC2与肿瘤化疗耐药实验研究进展

lncRNA CASC2与肿瘤化疗耐药实验研究进展

扫码查看
恶性肿瘤目前已经成为导致人类死亡的主要疾病,随着治疗过程中化疗药物使用时效不断延长,肿瘤细胞耐药性也不断增强.长链非编码 RNA(long non-coding RNA,lncRNA)是非编码 RNA家族的重要成员,癌症易感候选物 2(Cancer susceptibility candidate 2,CASC2)是一种长链非编码RNA,CASC2 高表达可以抑制肿瘤细胞发展,并可以通过促进耐药细胞凋亡、调节信号通路、参与细胞传导途径、竞争性结合miRNA以及改变蛋白结构或功能状态等机制来降低肿瘤细胞的耐药性.本文将对lncRNA CASC2 与恶性肿瘤化疗耐药调控作用及机制作一综述.
Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance
Malignant tumors have become the main cause of human death.With the prolonged use of chemotherapeutic drugs during the treatment process,tumor cell resistance is also constantly increasing.long non-coding RNA(lncRNA)is an important mem-ber of the non-coding RNA family.Cancer susceptibility candidate 2(CASC2)is a type of long non-coding RNA,high expression of CASC2 can inhibit tumor cell development and reduce drug resistance of tumor cells by promoting apoptosis,regulating signaling path-ways,participating in cellular transmission pathways,competitively binding of miRNA,and changing the protein structure or functional status.This article will provide a comprehensive review of the regulatory effects and mechanism of lncRNA CASC2 on chemotherapy resistance in malignant tumors.

long non-coding RNACancer susceptibility candidate 2ChemotherapyDrug resistanceTumor

尚宏悦、姚曼曼、路月亭、王迪娴、赵乾、刘铁军

展开 >

河北医科大学第四医院口腔科(石家庄 050011)

长链非编码RNA 癌症易感候选物2 化疗 耐药 肿瘤

2024

实用肿瘤学杂志
黑龙江省,辽宁省,吉林省肿瘤防治办公室

实用肿瘤学杂志

CSTPCD
影响因子:0.528
ISSN:1002-3070
年,卷(期):2024.38(1)
  • 4